BCR-ABL Quantitative MRD Monitor Test sale cost 1400 AED
Glucagon Test sale cost 1460 AED Glucagon Test Cost 1,630 د.إ Original price was: 1,630 د.إ.1,460 د.إCurrent price is: 1,460 د.إ.
FISH - NTRK 1 Gene Rearrangement Assay Test sale cost 1400 AED FISH - NTRK 1 Gene Rearrangement Assay Test Cost 1,560 د.إ Original price was: 1,560 د.إ.1,400 د.إCurrent price is: 1,400 د.إ.
Sale!

BCR-ABL Quantitative MRD Monitor Test Cost

Original price was: 1,560 د.إ.Current price is: 1,400 د.إ.

-10%

The BCR-ABL Quantitative MRD (Minimal Residual Disease) Monitor Test is a sophisticated diagnostic procedure employed to measure the amount of BCR-ABL fusion gene transcripts present in the blood or bone marrow of patients who have been diagnosed with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). This test is crucial for evaluating the effectiveness of therapy, predicting relapse, and guiding treatment decisions in individuals undergoing treatment for these types of leukemia.

Performed at DNA Labs UAE, a leading diagnostic facility, the test leverages advanced molecular techniques to provide accurate and sensitive detection of minimal residual disease, offering valuable insights into the patient’s response to treatment and disease progression. The cost of the BCR-ABL Quantitative MRD Monitor Test at DNA Labs UAE is set at 1400 AED, reflecting the comprehensive approach and cutting-edge technology utilized in this critical assessment. This test plays a pivotal role in personalized medicine, enabling healthcare providers to tailor treatment strategies based on the patient’s specific disease dynamics and response to therapy.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

BCR-ABL QUANTITATIVE MRD MONITOR Test

Components: Price 1400.0 AED

Sample Condition: 5 mL (3 mL min.) whole blood / Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.

Report Delivery: SampleMon / Wed / Fri by 9 am; Report Tue / Thu / Sat

Method: Real Time PCR

Test type: Leukemia

Doctor: Hematologist, Oncologist

Test Department: MOLECULAR DIAGNOSTICS

Pre Test Information: Duly filled MRD Requisition Form (Form 22) with historical data is mandatory.

Test Details

The BCR-ABL quantitative MRD monitor test is a diagnostic tool used to monitor the minimal residual disease (MRD) levels in patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who have undergone treatment with tyrosine kinase inhibitors (TKIs).

The test measures the levels of the BCR-ABL fusion gene, which is a genetic abnormality that drives the development of CML and a subset of ALL. The BCR-ABL gene produces a protein that promotes the uncontrolled growth of cancer cells.

The quantitative MRD monitor test uses a technique called polymerase chain reaction (PCR) to amplify and detect the BCR-ABL fusion gene in a patient’s blood or bone marrow sample. By measuring the levels of the fusion gene, the test can determine the amount of residual disease present after treatment.

Monitoring MRD levels is important in the management of CML and ALL because it helps assess the effectiveness of treatment and predict the likelihood of disease recurrence. Lower MRD levels indicate a better response to treatment and a lower risk of relapse.

The BCR-ABL quantitative MRD monitor test is typically performed at regular intervals during and after treatment to track the patient’s response and guide treatment decisions. The results of the test can help doctors determine if treatment adjustments are necessary or if the patient is in remission.

Overall, the BCR-ABL quantitative MRD monitor test is a valuable tool in the management of CML and ALL, allowing for personalized treatment and improved outcomes for patients.

Test Name BCR-ABL QUANTITATIVE MRD MONITOR Test
Components
Price 1400.0 AED
Sample Condition 5 mL (3 mL min.) whole blood \/ Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled MRD Requisition Form (Form 22) with historical data is mandatory.
Report Delivery SampleMon / Wed / Fri by 9 am; Report Tue / Thu / Sat
Method Real Time PCR
Test type Leukemia
Doctor Hematologist, Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled MRD Requisition Form (Form 22) with historical data is mandatory.
Test Details

The BCR-ABL quantitative MRD monitor test is a diagnostic tool used to monitor the minimal residual disease (MRD) levels in patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who have undergone treatment with tyrosine kinase inhibitors (TKIs).

The test measures the levels of the BCR-ABL fusion gene, which is a genetic abnormality that drives the development of CML and a subset of ALL. The BCR-ABL gene produces a protein that promotes the uncontrolled growth of cancer cells.

The quantitative MRD monitor test uses a technique called polymerase chain reaction (PCR) to amplify and detect the BCR-ABL fusion gene in a patient’s blood or bone marrow sample. By measuring the levels of the fusion gene, the test can determine the amount of residual disease present after treatment.

Monitoring MRD levels is important in the management of CML and ALL because it helps assess the effectiveness of treatment and predict the likelihood of disease recurrence. Lower MRD levels indicate a better response to treatment and a lower risk of relapse.

The BCR-ABL quantitative MRD monitor test is typically performed at regular intervals during and after treatment to track the patient’s response and guide treatment decisions. The results of the test can help doctors determine if treatment adjustments are necessary or if the patient is in remission.

Overall, the BCR-ABL quantitative MRD monitor test is a valuable tool in the management of CML and ALL, allowing for personalized treatment and improved outcomes for patients.

SKU: TEST-5392 Category:

Related products